Results 321 to 330 of about 775,670 (354)

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Cancer Cell, 2021
Jia-Tao Zhang, Chongrui Xu, Ying Cheng
exaly  

EGFR

2011
openaire   +2 more sources

EGFR

1998
Tak W. Mak, Josef Penninger, John Roder, Janet Rossant, Mary Saunders   +4 more
openaire   +1 more source

EGFR

2006
openaire   +2 more sources

EGFR signaling in renal fibrosis

Kidney International Supplements, 2014
Shougang Zhuang, Na Liu
exaly  

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

The Lancet Oncology, 2017
Yi-long Wu, Ying Cheng, Xiang-dong Zhou, K. Lee, K. Nakagawa, S. Niho, F. Tsuji, R. Linke, R. Rosell, J. Corral, M. Migliorino, A. Płużański, E. Sbar, Tao Wang, Jane Liang White, S. Nadanaciva, R. Sandin, T. Mok   +17 more
semanticscholar   +1 more source

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

Nature Reviews Clinical Oncology, 2009
Nicola Normanno, Floriana Morgillo, Antonella De Luca   +2 more
exaly  

EGFR

2017
openaire   +1 more source

EGFR

International Journal of Radiation Oncology*Biology*Physics, 2004
openaire   +1 more source

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Nature Reviews Clinical Oncology, 2010
Deric L Wheeler, Paul M Harari
exaly